Further prospective studies are warranted to determine whether antiangiogenic therapy can be administered as matched therapy for metastatic NSCLC in patients with TP53 hotspot mutations, especially those EAp53-HR patients with a high EAp53 score. The gene discussed is TP53; the disease is non-small cell lung carcinoma.